Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Amani et al., World Journal of Virology, doi:10.5501/wjv.v13.i1.88660, Mar 2024

Bamlanivimab/etesevimab for COVID-19

21st treatment shown to reduce risk in May 2021, now with p = 0.00049 from 22 studies, recognized in 11 countries. Efficacy is variant dependent.

No treatment is 100% effective.
Protocols combine treatments.

Meta-analysis of 30 studies with 47,368 COVID-19 patients showing lower mortality, hospitalization, and emergency department visits with bamlanivimab compared to standard of care/placebo.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron1-5.
Currently there are 22 bamlanivimab/etesevimab studies and meta-analysis shows:
OutcomeImprovement
Mortality51% lower [9‑74%]
Ventilation398% higher [-76‑10142%]
ICU admission28% lower [-11‑53%]
Hospitalization42% lower [30‑53%]
Cases57% fewer [33‑72%]
OutcomeImprovementEffect · pTreatmentControl
risk of death 49.8% lower · RR 0.50 · p < 0.001*** 49.8% lowerRR 0.50p < 0.001*** ,
risk of ICU admission 17.8% lower · RR 0.82 · p = 0.30 17.8% lowerRR 0.82p = 0.30 ,
risk of hospitalization 48.1% lower · RR 0.52 · p < 0.001*** 48.1% lowerRR 0.52p < 0.001*** ,
ER 30.9% lower · RR 0.69 · p = 0.05* 30.9% lowerRR 0.69p = 0.05* ,

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. * p < 0.05   *** p < 0.001

Amani et al., 25 Mar 2024, peer-reviewed, 6 authors. Contact: b89amani@yahoo.com.
Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Behnam Amani, Lida Khodavirdilou, Kourosh Rajabkhah, Vida Kardan Moghaddam, Arash Akbarzadeh, Bahman Amani
World Journal of Virology, doi:10.5501/wjv.v13.i1.88660
BACKGROUND Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19. AIM To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19. METHODS A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using "SARS-CoV-2", "COVID-19", "LY-CoV555", and "Bamlanivimab" keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data. RESULTS A total of 30 studies involving 47368 patients were included. A significant Amani B et al. Bamlanivimab for COVID-19 WJV https://www.wjgnet.com
References
Alam, Mahmud, Aggarwal, Fathma, Mahi et al., Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study, Cureus, doi:10.7759/cureus.14933
Amani, Bamlanivimab for COVID-19 WJV, doi:10.1172/JCI151697
Bariola, Mccreary, Wadas, Kip, Marroquin et al., Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Open Forum Infect Dis, doi:10.1093/ofid/ofab254
Beeraka, Sukocheva, Lukina, Liu, Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines, Rev Med Virol, doi:10.1002/rmv.2346
Boaventura, Macedo, Ribeiro, Jaconiano, Soares, Post-COVID-19 Condition: Where Are We Now?, Life, doi:10.3390/life12040517
Brock, Dagher, Wechsler, Lipe, Chaftari et al., Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19, Open Forum Infect Dis, doi:10.1093/ofid/ofab466.741
Bull-Otterson, Baca, Saydah, Boehmer, Adjei et al., Post-COVID conditions among adult COVID-19 survivors aged 18-64 and≥ 65 years-United States, March 2020-November 2021, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7121e1
Center, Suite 160
Ceramella, Iacopetta, Sinicropi, Andreu, Mariconda et al., Drugs for COVID-19: An Update, Molecules, doi:10.3390/molecules27238562
Chen, Datta, Li, Chien, Price et al., First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.2405
Chen, Nirula, Heller, Gottlieb, Boscia et al., BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2029849
Cheng, Reyes, Satram, Birch, Gibbons et al., Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA, Infect Dis Ther, doi:10.1007/s40121-022-00755-0
Chew, Moser, Daar, Wohl, Li et al., Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19, Nat Commun, doi:10.1038/s41467-022-32551-2
Choudhary, Chew, Deo, Flynn, Regan et al., ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial, Nat Microbiol, doi:10.1038/s41564-022-01254-1
Cooper, Christensen, Salazar, Perez, Graviss et al., Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study, Open Forum Infect Dis, doi:10.1093/ofid/ofab512
Corwin, Ender, Sahu, Durgham, Mcgorry et al., The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting, Open Forum Infect Dis, doi:10.1093/ofid/ofab305
Cox, Peacock, Harvey, Hughes, Wright et al., SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat Rev Microbiol, doi:10.1038/s41579-022-00809-7
Destache, Aurit, Schmidt, Erkes, Tierney et al., Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design, Pharmacotherapy, doi:10.1002/phar.2613
Djuric, Bogicevic, Pešić, Davidovic, Naumovic, MO659: First Experience of Bamlanivimab for Covid-19 Positive Haemodialysis Patients: A Case-Control Study, Nephrol Dial Transplant, doi:10.1093/ndt/gfac077.019
Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2102685
Farcy, Dalley, Miro, Swalley, Sherman et al., A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital, J Emerg Med, doi:10.1016/j.jemermed.2021.07.025
Filippo, Crovetto, Bucek, Nahass, Milano et al., Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis, Open Forum Infect Dis, doi:10.1093/ofid/ofac080
Ganesh, Pawlowski, Horo, Arndt, Arndt et al., Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19, J Clin Invest
Ganesh, Philpot, Bierle, Anderson, Arndt et al., Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, J Infect Dis, doi:10.1093/infdis/jiab377
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, N Engl J Med, doi:10.1056/NEJMoa2033130
Heller, Henrici, Büttner, Leube, Treske et al., SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab, Int J Infect Dis, doi:10.1016/j.ijid.2023.01.012
Higgins, Altman, Gøtzsche, Jüni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, doi:10.1136/bmj.d5928
Hoffmann, Hofmann-Winkler, Krüger, Kempf, Nehlmeier et al., SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination, Cell Rep, doi:10.1016/j.celrep.2021.109415
Huang, Mccreary, Bariola, Minnier, Wadas et al., Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.20957
Iqbal, Terlau, Hernandez, Woods, Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community, Cureus, doi:10.7759/cureus.16477
Karr, Chung, Burtson, Markert, Kelly, Bamlanivimab Use in a Military Treatment Facility, Mil Med, doi:10.1093/milmed/usab188
Kertes, Shapiro, David, Engel-Zohar, Rosen et al., Bamlanivimab for COVID-19 WJV
Kumar, Wu, Stosor, Moore, Achenbach et al., Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study, Clin Infect Dis, doi:10.1093/cid/ciab305
Lanzavecchia, Beyer, Bolo, Vaccination Is Not Enough: Understanding the Increase in Cases of COVID-19 in Chile despite a High Vaccination Rate, Epidemiologia, doi:10.3390/epidemiologia2030028
Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study, Int Immunopharmacol, doi:10.1016/j.intimp.2022.108570
Lin, Hung, Lai, Wang, Chen, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials, J Med Virol, doi:10.1002/jmv.27623
Liu, Arase, Neutralizing and enhancing antibodies against SARS-CoV-2, Inflamm Regen, doi:10.1186/s41232-022-00233-7
Mccreary, Bariola, Minnier, Wadas, Shovel et al., A learning health system randomized trial of monoclonal antibodies for COVID-19, doi:10.1101/2021.09.03.21262551
Moher, Liberati, Tetzlaff, Altman, Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, doi:10.1371/journal.pmed.1000097
Monday, Brar, Alangaden, Ramesh, SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities, J Clin Pharm Ther, doi:10.1111/jcpt.13694
Murillo, Lomiguen, Terrell, King, Lin et al., Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents, Aging Dis, doi:10.14336/AD.2022.0205
Peiffer-Smadja, Bridier-Nahmias, Ferré, Charpentier, Garé et al., Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2, Viruses, doi:10.3390/v13081642
Priest, Blanchette, Hekman, Maddikunta, Burleson, Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2-Positive Patients in a Regional Health Care System, Infect Dis Clin Pract
Quenzer, Lafree, Grey, Singh, Smyers et al., Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals, West J Emerg Med, doi:10.5811/westjem.2021.10.52668
Razonable, Pawlowski, Horo, Arndt, Arndt et al., Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102
Rubin, Boiarsky, Canha, Giobbie-Hurder, Liu et al., Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process, Open Forum Infect Dis, doi:10.1093/ofid/ofab546
Savoldi, Morra, Nardo, Cattelan, Mirandola et al., Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-022-04464-x
Sridhara, Gungor, Erol, Al-Obaidi, Zangeneh et al., Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era, PLoS One, doi:10.1371/journal.pone.0279326
Sterne, Hernán, Reeves, Savović, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ, doi:10.1136/bmj.i4919
Sukocheva, Maksoud, Beeraka, Madhunapantula, Sinelnikov et al., Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome, J Adv Res, doi:10.1016/j.jare.2021.11.013
Tao, Tzou, Pond, Ioannidis, Shafer, Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis, Microbiol Spectr, doi:10.1128/spectrum.00926-22
Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nat Rev Immunol, doi:10.1038/s41577-021-00542-x
Vena, Cenderello, Balletto, Mezzogori, Barbone et al., Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region, J Clin Med, doi:10.3390/jcm10204682
Voelker, Jerath, Monoclonal antibody infusion for COVID-19 infection: results from a tertiary referral center, J Allergy Clin Immunol, doi:10.1016/j.jaci.2021.12.639
Webb, Buckel, Vento, Butler, Grisel et al., Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19, Open Forum Infect Dis, doi:10.1093/ofid/ofab331
Xiang, He, Li, Cheng, Zhang et al., Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis, J Med Virol, doi:10.1002/jmv.27542
Zuo, Ao, Wang, Gao, Qi, Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis, J Infect, doi:10.1016/j.jinf.2021.09.003
DOI record: { "DOI": "10.5501/wjv.v13.i1.88660", "ISSN": [ "2220-3249" ], "URL": "http://dx.doi.org/10.5501/wjv.v13.i1.88660", "abstract": "<jats:p>BACKGROUND</jats:p>\n <jats:p>Monoclonal antibodies (mAbs) have shown clinical benefits against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Several studies have reported the use of bamlanivimab as a promising treatment option for COVID-19.</jats:p>\n <jats:p>AIM</jats:p>\n <jats:p>To synthesize the latest evidence for the efficacy and safety of bamlanivimab alone in the treatment of adult patients with COVID-19.</jats:p>\n <jats:p>METHODS</jats:p>\n <jats:p>A literature search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar using “SARS‑CoV‑2”, “COVID-19”, “LY-CoV555”, and “Bamlanivimab” keywords up to January 25, 2023. The quality of included studies was assessed using the Cochrane bias tools. The Comprehensive Meta-Analysis software version 3.0 was used to analyze the data.</jats:p>\n <jats:p>RESULTS</jats:p>\n <jats:p>A total of 30 studies involving 47368 patients were included. A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate [risk ratio (RR) = 50, 95% confidence interval (CI): 0.36-0.70], hospitalization rate (RR = 0.51; 95%CI: 0.39-0.68), and emergency department (ED) visits (RR = 0.69; 95%CI: 0.47-0.99); while the two groups exhibited no significant difference in terms of intensive care unit (ICU) admission (P &gt; 0.05). Compared to other mAbs, bamlanivimab was associated with a higher rate of hospitalization (RR = 1.44; 95%CI: 1.07-1.94). However, no significant difference was detected between the bamlanivimab and other mAbs groups in terms of mortality rate, ICU admission, and ED (P &gt; 0.05). The incidence of any adverse events was similar between the bamlanivimab and control groups (P &gt; 0.05).</jats:p>\n <jats:p>CONCLUSION</jats:p>\n <jats:p>Although the results suggest the efficacy and safety of bamlanivimab in COVID-19 patients, further research is required to confirm the efficacy of this drug for the current circulating SARS-CoV-2 variants.</jats:p>", "alternative-id": [ "88660" ], "author": [ { "affiliation": [], "family": "Amani", "given": "Behnam", "sequence": "first" }, { "affiliation": [], "family": "Khodavirdilou", "given": "Lida", "sequence": "additional" }, { "affiliation": [], "family": "Rajabkhah", "given": "Kourosh", "sequence": "additional" }, { "affiliation": [], "family": "Kardan Moghaddam", "given": "Vida", "sequence": "additional" }, { "affiliation": [], "family": "Akbarzadeh", "given": "Arash", "sequence": "additional" }, { "affiliation": [], "family": "Amani", "given": "Bahman", "sequence": "additional" } ], "container-title": "World Journal of Virology", "container-title-short": "World J Virol", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 3, 11 ] ], "date-time": "2024-03-11T08:54:45Z", "timestamp": 1710147285000 }, "deposited": { "date-parts": [ [ 2024, 3, 11 ] ], "date-time": "2024-03-11T08:55:27Z", "timestamp": 1710147327000 }, "indexed": { "date-parts": [ [ 2024, 3, 12 ] ], "date-time": "2024-03-12T00:26:41Z", "timestamp": 1710203201522 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2024, 3, 25 ] ] }, "journal-issue": { "issue": "1" }, "link": [ { "URL": "https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "2060", "original-title": [], "prefix": "10.5501", "published": { "date-parts": [ [ 2024, 3, 25 ] ] }, "published-online": { "date-parts": [ [ 2024, 3, 25 ] ] }, "publisher": "Baishideng Publishing Group Inc.", "reference": [ { "DOI": "10.3390/epidemiologia2030028", "doi-asserted-by": "publisher", "key": "B1" }, { "DOI": "10.3390/molecules27238562", "doi-asserted-by": "publisher", "key": "B2" }, { "DOI": "10.1001/jamanetworkopen.2022.20957", "doi-asserted-by": "publisher", "key": "B3" }, { "DOI": "10.1016/j.eclinm.2021.101102", "doi-asserted-by": "publisher", "key": "B4" }, { "DOI": "10.1093/cid/ciac625", "doi-asserted-by": "publisher", "key": "B5" }, { "DOI": "10.1016/j.intimp.2022.108570", "doi-asserted-by": "publisher", "key": "B6" }, { "DOI": "10.3390/jcm10204682", "doi-asserted-by": "publisher", "key": "B7" }, { "DOI": "10.7759/cureus.16477", "doi-asserted-by": "publisher", "key": "B8" }, { "DOI": "10.1038/s41577-021-00542-x", "doi-asserted-by": "publisher", "key": "B9" }, { "DOI": "10.1093/milmed/usab188", "doi-asserted-by": "publisher", "key": "B10" }, { "DOI": "10.1016/j.jemermed.2021.07.025", "doi-asserted-by": "publisher", "key": "B11" }, { "DOI": "10.1056/NEJMoa2102685", "doi-asserted-by": "publisher", "key": "B12" }, { "DOI": "10.1093/ofid/ofab254", "doi-asserted-by": "publisher", "key": "B13" }, { "DOI": "10.1002/phar.2613", "doi-asserted-by": "publisher", "key": "B14" }, { "DOI": "10.1128/spectrum.00926-22", "doi-asserted-by": "publisher", "key": "B15" }, { "DOI": "10.1371/journal.pmed.1000097", "doi-asserted-by": "publisher", "key": "B16" }, { "DOI": "10.1136/bmj.i4919", "doi-asserted-by": "publisher", "key": "B17" }, { "DOI": "10.1136/bmj.d5928", "doi-asserted-by": "publisher", "key": "B18" }, { "DOI": "10.7759/cureus.14933", "doi-asserted-by": "publisher", "key": "B19" }, { "DOI": "10.1093/ofid/ofab466.741", "doi-asserted-by": "publisher", "key": "B20" }, { "DOI": "10.1002/cpt.2405", "doi-asserted-by": "publisher", "key": "B21" }, { "DOI": "10.1056/NEJMoa2029849", "doi-asserted-by": "publisher", "key": "B22" }, { "DOI": "10.1038/s41467-022-32551-2", "doi-asserted-by": "publisher", "key": "B23" }, { "DOI": "10.1093/ofid/ofab512", "doi-asserted-by": "publisher", "key": "B24" }, { "DOI": "10.1093/ofid/ofab305", "doi-asserted-by": "publisher", "key": "B25" }, { "DOI": "10.1093/ndt/gfac077.019", "doi-asserted-by": "publisher", "key": "B26" }, { "DOI": "10.1172/JCI151697", "doi-asserted-by": "publisher", "key": "B27" }, { "DOI": "10.1093/infdis/jiab377", "doi-asserted-by": "publisher", "key": "B28" }, { "DOI": "10.1001/jama.2021.0202", "doi-asserted-by": "publisher", "key": "B29" }, { "DOI": "10.1056/NEJMoa2033130", "doi-asserted-by": "publisher", "key": "B30" }, { "DOI": "10.1016/j.ijid.2023.01.012", "doi-asserted-by": "publisher", "key": "B31" }, { "DOI": "10.1093/cid/ciab305", "doi-asserted-by": "publisher", "key": "B32" }, { "DOI": "10.1101/2021.09.03.21262551", "doi-asserted-by": "publisher", "key": "B33" }, { "DOI": "10.1111/jcpt.13694", "doi-asserted-by": "publisher", "key": "B34" }, { "DOI": "10.14336/AD.2022.0205", "doi-asserted-by": "publisher", "key": "B35" }, { "DOI": "10.1097/IPC.0000000000001130", "doi-asserted-by": "crossref", "key": "B36", "unstructured": "Priest DH, Blanchette LM, Hekman AL, Maddikunta R, Burleson PE. Bamlanivimab for the Prevention of Hospitalizations and Emergency Department Visits in SARS-CoV-2-Positive Patients in a Regional Health Care System. Infect Dis Clin Pract 2022; 30: 1-4" }, { "DOI": "10.5811/westjem.2021.10.52668", "doi-asserted-by": "publisher", "key": "B37" }, { "DOI": "10.1093/ofid/ofab546", "doi-asserted-by": "publisher", "key": "B38" }, { "DOI": "10.1093/ofid/ofac080", "doi-asserted-by": "publisher", "key": "B39" }, { "DOI": "10.1007/s10096-022-04464-x", "doi-asserted-by": "publisher", "key": "B40" }, { "DOI": "10.1371/journal.pone.0279326", "doi-asserted-by": "publisher", "key": "B41" }, { "DOI": "10.1016/j.jaci.2021.12.639", "doi-asserted-by": "publisher", "key": "B42" }, { "DOI": "10.1093/ofid/ofab331", "doi-asserted-by": "publisher", "key": "B43" }, { "DOI": "10.1186/s41232-022-00233-7", "doi-asserted-by": "publisher", "key": "B44" }, { "DOI": "10.1002/jmv.27542", "doi-asserted-by": "publisher", "key": "B45" }, { "DOI": "10.1016/j.jinf.2021.09.003", "doi-asserted-by": "publisher", "key": "B46" }, { "DOI": "10.1007/s40121-022-00755-0", "doi-asserted-by": "publisher", "key": "B47" }, { "DOI": "10.1038/s41579-022-00809-7", "doi-asserted-by": "publisher", "key": "B48" }, { "DOI": "10.1002/jmv.27623", "doi-asserted-by": "publisher", "key": "B49" }, { "DOI": "10.3390/life12040517", "doi-asserted-by": "publisher", "key": "B50" }, { "DOI": "10.15585/mmwr.mm7121e1", "doi-asserted-by": "publisher", "key": "B51" }, { "DOI": "10.1016/j.jare.2021.11.013", "doi-asserted-by": "publisher", "key": "B52" }, { "DOI": "10.1016/j.celrep.2021.109415", "doi-asserted-by": "publisher", "key": "B53" }, { "DOI": "10.3390/v13081642", "doi-asserted-by": "publisher", "key": "B54" }, { "DOI": "10.1038/s41564-022-01254-1", "doi-asserted-by": "publisher", "key": "B55" }, { "DOI": "10.1002/rmv.2346", "doi-asserted-by": "publisher", "key": "B56" } ], "reference-count": 56, "references-count": 56, "relation": {}, "resource": { "primary": { "URL": "https://www.wjgnet.com/2220-3249/full/v13/i1/88660.htm" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis", "type": "journal-article", "volume": "13" }